S&P 500 Healthcare Sector SEC Filings — September 04, 2026

EVP and Worldwide Chair of MedTech Timothy Schmid sold 22,527 shares at $274.74, worth approximately $6.19 million, the largest and only clearly discretionary-looking disposition in the batch

Schmid retained 25,447 shares after the reported transactions, indicating the sale did not fully eliminate his direct exposure; this moderates, but does not remove, the negative signal

The filing included option exercises/conversions of 11,070 shares at $131.94 and 22,527 shares at $151.41 before related sales, suggesting the reported activity may partly reflect equity-compensation monetization rather than an outright open-market exit

CFO Wayne DeVeydt withheld 1,208.895 shares at $399.66, approximately $483,000, for taxes and retained 18,569.525 shares; the substantial remaining holding argues against interpreting the filing as a broad management exit

EVP and Chief Legal Officer Erin Wessling had 399 shares withheld across two transactions at $405.84 and $414.78, totaling approximately $144,000; the activity is classified as tax withholding and provides limited directional information

Wessling retained 7,230 shares after the transactions, preserving meaningful ongoing exposure despite the administrative share reductions

EVP and Chief Human Resources Officer Ryan Craig withheld 144 shares at $405.84, approximately $58,400, and retained 6,530 shares; continued ownership makes this a low-conviction signal

Two senior executives gifted 229 shares in aggregate—13 shares from manufacturing operations executive Edgardo Hernandez and 216 shares from Chief People Officer Eric Dozier—without reported sales or purchases

The gifting executives retained 46,082.717 and 14,239.212 shares, respectively, after their transactions, indicating that neither filing represents a material reduction in reported holdings

Four of the six filings involve tax withholding or gifting rather than discretionary purchases or sales, so the batch provides little evidence of broad sector-wide management conviction; J&J is the key outlier by transaction value and sentiment

The $6.19 million MedTech executive sale is materially larger than the other reported transactions and is the only filing marked negative, creating a specific management-confidence signal to investigate

The combination of option exercises, conversions, and sales can obscure the extent of discretionary selling; investors should review subsequent Form 4 filings for additional sales or changes in retained ownership

The CFO's approximately $483,000 tax withholding is sizable in absolute terms, although the 18,569.525-share remaining position and withholding classification reduce its bearish significance

Two separate senior executives reported tax-withholding transactions on the same date, totaling 543 shares across the company; this is not evidence of selling conviction but merits monitoring for follow-on discretionary trades

No revenue, earnings, margin, leverage, guidance, or period-comparison data were included in this batch, limiting the ability to validate whether insider activity is supported or contradicted by fundamentals

All six filings are insider-transaction Form 4 disclosures, leaving no new evidence on regulatory outcomes, product catalysts, reimbursement trends, capital allocation, or upcoming earnings expectations

The two gifts are not inherently bearish, but repeated gifts should be distinguished from open-market sales in future filings to avoid missing a developing reduction in insider exposure

Use Schmid's $6.19 million sale as a due-diligence trigger rather than an automatic short signal; review MedTech operating trends and subsequent insider filings for confirmation or reversal

Schmid retained 25,447 shares after the transactions, leaving scope for a constructive interpretation if no additional sales follow and operating disclosures remain stable

The CFO retained 18,569.525 shares after a tax withholding worth approximately $483,000; any market reaction that treats this as discretionary selling could create a potential entry point, subject to fundamental confirmation

Wessling and Craig retained 7,230 and 6,530 shares, respectively, after tax withholdings; stable or increasing subsequent holdings would support an alignment thesis

Hernandez retained 46,082.717 shares and Dozier retained 14,239.212 shares after small gifts, indicating substantial ongoing exposure that may be more informative than the gifts themselves

Because the current batch lacks purchases and contains mainly administrative transactions, a future cluster of open-market buying would represent a more actionable positive signal than the present filings

J&J is the only company with a multi-million-dollar sale and negative sentiment, making it the highest-priority candidate for event-driven research versus the lower-materiality Elevance, Lilly, and UnitedHealth disclosures

Compare future discretionary sales against retained ownership—particularly for Schmid and DeVeydt—to distinguish routine compensation-related activity from genuine management de-risking

Four of six filings involve tax withholding or gifting, while no filing reports open-market insider buying; the batch therefore offers limited evidence of broad bullish management conviction.

Johnson & Johnson's approximately $6.19 million MedTech executive sale is substantially larger than the approximately $483,000 UnitedHealth withholding and the smaller Elevance and Eli Lilly transactions, concentrating the sector's bearish insider signal in one company.

Reported post-transaction holdings include 25,447 shares for J&J's Schmid, 18,569.525 for UnitedHealth's DeVeydt, 7,230 and 6,530 for Elevance executives, and 46,082.717 and 14,239.212 for Lilly executives; the filings generally show continued exposure rather than complete exits.

The supplied filings contain no period-over-period revenue, earnings, margin, leverage, or operating metrics, preventing aggregation of sector growth or profitability trends and requiring investors to source confirmation from earnings materials.

There are no reported dividend changes, buybacks, M&A terms, guidance updates, or forward targets in the enriched data provided, so the current digest is an insider-activity monitor rather than a fundamental sector update.

The filings span insurers, pharmaceuticals, medical technology, and healthcare services, but the activity does not form a common directional pattern; the primary cross-sector conclusion is mixed and low-conviction outside the J&J sale.

Monitor for additional open-market sales, changes in the retained 25,447-share position, or further option-related transactions after the approximately $6.19 million MedTech sale reported on 2026-09-04.

Reconcile the insider sale with the next available MedTech revenue, margin, product, regulatory, and guidance disclosures; none were provided in the current filing.

Track whether the CFO makes discretionary sales after the 1,208.895-share tax withholding or maintains the 18,569.525-share position.

Monitor Wessling and Craig for additional sales or purchases following tax withholdings totaling 543 shares across the reported filings.

Distinguish future gifts from open-market sales and monitor whether Hernandez or Dozier materially reduce their remaining holdings of 46,082.717 and 14,239.212 shares.

Seek the next earnings releases, earnings calls, and SEC filings for revenue growth, margin direction, guidance, reimbursement, product, and regulatory updates, because none are included here.

Watch for the first open-market insider purchases or a broader cluster of discretionary sales across the covered healthcare constituents; the current six-filing sample is dominated by withholding and gifting.

The filings were reported for 2026-09-04; use subsequent Form 4 submissions and the next scheduled company disclosures to determine whether the J&J transaction is isolated or the start of a broader pattern.